Small molecule · Inhibitor of Protein kinase C · developed by IDEAYA Biosciences
Darovasertib is an orally available small molecule that binds and inhibits protein kinase C (PKC), a serine/threonine kinase involved in tumor cell proliferation, invasion and survival. It is being studied in metastatic uveal melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07015190 | Phase 3 | Uveal Melanoma | Recruiting | IDYA |
| NCT05987332 | Phase 2/3 | Metastatic Uveal Melanoma | Active not recruiting | IDYA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Uveal MelanomaUveal Melanoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the IDYA page.
See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IDYA catalysts and pipeline →